Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes Prevention (ELEVATE-DP)

Award Number: R18DK110739
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: KDA (KNOWLEDGE/DEVELOPMENT/APPLICATION)
PERIOD OF PERFORMANCE START DATE: 04/01/2017
PERIOD OF PERFORMANCE END DATE: 03/31/2023

Group Awards By:

View Award Description

Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes Prevention (ELEVATE-DP) - PROJECT SUMMARY/ABSTRACT The Diabetes Prevention Program was a landmark randomized controlled trial that demonstrated the efficacy of a structured and comprehensive lifestyle intervention in preventing type 2 diabetes (T2D). Due to its large success, it was adapted for use in community settings by changing the intensive, individualized (one-on- one) lifestyle intervention to a facilitated, group-based intervention (Group Lifestyle Balance™ [GLB]). While the GLB program has been associated with modest improvements in weight management and a reduced incidence of T2D in various community-based settings, reach has been limited. Healthcare system settings hold great potential for implementing behavioral lifestyle interventions due to the clinical resources and access to patients at risk for T2D. Natural experiments resulting from the spontaneous and organic implementation of evidence-based interventions, such as GLB, into a real-world clinical practice provide a rare and exciting opportunity to examine effectiveness in a truly pragmatic context. In the proposed study, Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes Prevention (ELEVATE-DP), we seek to evaluate the GLB program after its integration within a large, healthcare delivery system, Sutter Health (SH) of Northern California. SH is a mixed payer environment and operates as a fee-for-service organization, much like the U.S. healthcare system as a whole. In 2010, two of the five regional affiliates independently launched GLB programs. This allows for the unique opportunity to rigorously evaluate the real-world effectiveness of the GLB program after integration within a healthcare system, with high potential for the generalizability of findings to other similar health systems in the U.S. This study will employ a rigorous mixed-methods evaluation approach, using a large, comprehensive electronic health records (EHR) system, GLB program records, and prospectively collected primary data from past and present GLB administrators, facilitators, and participants, as well as eligible non-participants. We will use the EHR to retrospectively identify GLB participants (N=5,000) and a matched usual-care cohort (non-GLB participants; N=10,000) between 2010 and 2016, and will add four years of additional data (2017-2020). The Specific Aims are to: 1) Evaluate the clinical effectiveness of GLB relative to usual-care; 2) Evaluate the impact of GLB on healthcare resource utilization and costs relative to usual-care, including a formal cost-effectiveness analysis; and 3) Evaluate the implementation and fidelity of GLB within and across SH regional divisions and clinics using a comparative mixed-methods process evaluation. This study will identify important barriers to and facilitators of translating an efficacious diabetes prevention intervention into routine clinical practice, outside of a research setting.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$80,312 )
2024	2021	PALO ALTO MED CLINC RESEARCH INSTITUTE	795 EL CAMINO REAL # A	PALO ALTO	CA	94301	SANTA CLARA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	11/20/2023	NON-COMPETING CONTINUATION	-$80,312
														Subtotal = -$80,312

Issue Date FY: 2021 ( Subtotal = $601,379 )
2021	2021	PALO ALTO MEDICAL FOUNDATION FOR HEALTH CARE, RESEARCH AND EDUCATION (INC)	795 EL CAMINO REAL	PALO ALTO	CA	94301	SANTA CLARA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	8/4/2021	NON-COMPETING CONTINUATION	$601,379
														Subtotal = $601,379

Issue Date FY: 2020 ( Subtotal = $611,515 )
2020	2020	PALO ALTO MEDICAL FOUNDATION FOR HEALTH CARE, RESEARCH AND EDUCATION (INC)	795 EL CAMINO REAL	PALO ALTO	CA	94301	SANTA CLARA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	4/8/2020	NON-COMPETING CONTINUATION	$611,515
														Subtotal = $611,515

Issue Date FY: 2019 ( Subtotal = $639,600 )
2019	2019	PALO ALTO MEDICAL FOUNDATION FOR HEALTH CARE, RESEARCH AND EDUCATION (INC)	795 EL CAMINO REAL	PALO ALTO	CA	94301	SANTA CLARA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	4/30/2019	NON-COMPETING CONTINUATION	$639,600
														Subtotal = $639,600

Issue Date FY: 2018 ( Subtotal = $664,238 )
2018	2018	PALO ALTO MEDICAL FOUNDATION FOR HEALTH CARE, RESEARCH AND EDUCATION (INC)	795 EL CAMINO REAL	PALO ALTO	CA	94301	SANTA CLARA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	4/25/2018	NON-COMPETING CONTINUATION	$664,238
														Subtotal = $664,238

Issue Date FY: 2017 ( Subtotal = $688,662 )
2017	2017	PALO ALTO MEDICAL FOUNDATION FOR HEALTH CARE, RESEARCH AND EDUCATION (INC)	795 EL CAMINO REAL	PALO ALTO	CA	94301	SANTA CLARA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	3/15/2017	NEW	$688,662
														Subtotal = $688,662

Grand Total All Awards = $3,125,082

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes Prevention (ELEVATE-DP)

Award Number: R18DK110739

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: KDA (KNOWLEDGE/DEVELOPMENT/APPLICATION)

PERIOD OF PERFORMANCE START DATE: 04/01/2017

PERIOD OF PERFORMANCE END DATE: 03/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer